Present and future evolution of advanced breast cancer therapy.
Although the introduction of novel therapies and drug combinations has improved the prognosis of metastatic breast cancer, the disease remains incurable. Increased knowledge of the biology and the molecular alterations in breast cancer has facilitated the design of targeted therapies. These agents include receptor and nonreceptor tyrosine kinase inhibitors (epidermal growth factor receptor family), intracellular signaling pathways (phosphatidylinositol-3-kinase, AKT, mammalian target of rapamycin) angiogenesis inhibitors and agents that interfere with DNA repair (poly(ADP-ribose) polymerase inhibitors). In the present review, we present the most promising studies of these new targeted therapies and novel combinations of targeted therapies with cytotoxic agents.
Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1155 Herman P, Pressler, CPB5.3458, Houston, TX 77030-3721, USA. ralvarez@mdanderson.org
Ricardo H
RH
Alvarez
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods